HF
INSY

Hoxton Financial’s Insys Therapeutics, Inc. INSY Stock Holding History

Hoxton Financial’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-354
Closed -$5K – 637
2013
Q4 		$5K Buy
354
+120
+51% +$1.66K ﹤0.01% 539
2013
Q3 		$3K Buy
+234
New +$1.92K ﹤0.01% 367

Other funds holding INSY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hoxton Financial's INSY Position: Q1 2014 in Review

Hoxton Financial sold out of Insys Therapeutics, Inc. (INSY) in Q1 2014, closing a stake of 354 shares — an estimated $5K sold.

Hoxton Financial first reported a position in INSY in Q3 2013 and held it in 2 quarters. The position peaked at $5K in Q4 2013. 99 funds tracked by Wall St. Rank hold INSY as of Q1 2014.

  • Hoxton Financial reported no remaining Insys Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • Hoxton Financial sold 354 Insys Therapeutics, Inc. shares in Q1 2014, an estimated $5K.
  • Hoxton Financial first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 2 quarters.
  • Hoxton Financial's Insys Therapeutics, Inc. position peaked at $5K in Q4 2013.
  • 99 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2014.

Based on Hoxton Financial's 13F filing for Q1 2014, filed 25 Apr 2014.